| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10917832 | Radiotherapy and Oncology | 2016 | 7 Pages |
Abstract
CTII plus FOLFIRI improves the LCT with tolerable toxicities as a second-line treatment in patients with local recurrent rectal cancer, and is helpful to prolong the OS, particularly in patients without distant metastases or with a history of radiotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Liangrong Shi, Xiaodong Li, Honglei Pei, Jiemin Zhao, Weiguang Qiang, Jin Wang, Bin Xu, Lujun Chen, Jun Wu, Mei Ji, Qicheng Lu, Zhong Li, Haitao Wang, Jingting Jiang, Changping Wu,